医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

China’s Center for Drug Evaluation of the National Medical Products Administration Commits to CDISC Standards

2019年12月18日 AM04:36
このエントリーをはてなブックマークに追加


 

AUSTIN, Texas

The Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has released the requirements of clinical trial data submission in the electronic common technical document (eCTD) for public review in October. CDISC standards are now the preferred standards for electronic data submission in China. The new eCTD stipulates the use of SDTM, CDISC’s standard for formatting and organizing study data, and ADaM, CDISC’s standard for data analysis, for pharmaceutical sponsors submitting datasets in clinical trial databases and related materials. Going forward, CDISC standards are the only global data standard the CDE has recommended.

The NMPA joins the US FDA and Japan PMDA in recognizing the centrality of global CDISC standards to be used for submission of clinical research study data. Requiring standardized data enables regulators to modernize the review process with a more consistent use of analysis tools to better view drug data and highlight areas of concern. CDISC standards streamline the review process and expedite approval times for more efficient and effective clinical research.

“CDISC commends the CDE and all involved in developing the eCTD, which is well-aligned with how CDISC standards are utilized globally,” said David R. Bobbitt, MSc, MBA, CDISC President and CEO. “This development represents a strengthening of the relationship between NMPA and CDISC, while supporting continued positive development of the Chinese pharmaceutical industry.”

“CDISC standards are now more than ever the global standard,” added Bobbitt.

Since 2012, the community of CDISC users in China has grown significantly as members of the Chinese CDISC Coordinating Council (C3C) promote awareness and support the implementation of CDISC standards.

About CDISC

CDISC creates clarity in clinical research by convening a global community to develop and advance data standards of the highest quality. Required by the United States Food and Drug Administration (FDA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and adopted by the world’s leading research organizations, CDISC standards enable the accessibility, interoperability, and reusability of data. With the help of CDISC standards, the entire research community can maximize the value of data for more efficient and meaningful research that has invaluable impact on global health. CDISC is a 501(c)(3) global nonprofit charitable organization and is headquartered in Austin, Texas, with hundreds of employees, volunteers, and member organizations around the world.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191217005785/en/

CONTACT

Ann P. White

+1.512.363.5826

awhite@cdisc.org

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作